今天是:   返回主页   |   加入收藏   |   联系我们
引用本文:
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  下载PDF阅读器  关闭
附件
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 640次   下载 380 本文二维码信息
码上扫一扫!
分享到: 微信 更多
宣肺败毒颗粒治疗奥密克戎毒株感染新型冠状病毒肺炎临床疗效评价研究
庞稳泰1, 杨丰文1, 郑文科1, 封继宏2, 徐强2, 张磊3
1.天津中医药大学循证医学中心, 天津 301617;2.天津中医药大学第二附属医院, 天津 300150;3.天津医院, 天津 300210
摘要:
[目的] 评价宣肺败毒颗粒治疗奥密克戎毒株感染的新型冠状病毒肺炎(COVID-19)的有效性及安全性。[方法] 研究共纳入180例奥密克戎毒株感染的轻型/普通型COVID-19患者。根据患者意愿分组,试验组接受宣肺败毒颗粒联合常规治疗(120例),对照组接受常规治疗(60例)。主要疗效评价指标为病毒核酸转阴时间、住院时间,次要指标为7 d症状消失率、重症率及病死率,安全性指标为不良事件。[结果] 试验组的病毒核酸转阴时间为8(6,10)d,住院时间为11(9,13)d,均短于对照组的10(7,11)d与12(10.5,13.5)d,组间差异有统计学意义(P<0.05)。在咳嗽、咯痰、咽喉不适、口干等症状消失率方面,试验组优于对照组,两组均未发生重症及死亡,亦未观察到治疗相关不良事件。[结论] 在奥密克戎毒株感染COVID-19的治疗中,宣肺败毒颗粒能缩短病毒核酸转阴时间,促进症状消失,具有良好的安全性。
关键词:  新型冠状病毒肺炎  奥密克戎毒株  中医药  宣肺败毒颗粒  临床评价
DOI:10.11656/j.issn.1672-1519.2022.09.02
分类号:R254
基金项目:国家自然科学基金项目(82004505);国家重点研发计划项目(2021YFC0863200)。
Clinical efficacy evaluation of Xuanfei Baidu Granule in the treatment of Omicron virus infection with COVID-19
PANG Wentai1, YANG Fengwen1, ZHENG Wenke1, FENG Jihong2, XU Qiang2, ZHANG Lei3
1.Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;2.Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China;3.Tianjin Hospital, Tianjin 300210, China
Abstract:
[Objective] To evaluate the efficacy and safety of Xuanfei Baidu Granule (XFBD) in the treatment of COVID-19 infected with Omicron virus strain.[Methods] A total of 180 patients with mild/normal COVID-19 infected with Omicron strain were included.Patients were assigned into two groups according to their wishes:the experimental group received XFBD combined with conventional treatment (120 cases),the control group received conventional treatment (60 cases).The primary outcomes were virus nucleic acid negative conversion time and length of hospital stay.The secondary outcomes were symptom disappearance rate,severe case rate and mortality rate.The safety outcomes were adverse events.[Results] The time of virus nucleic acid turning negative in the experimental group was 8(6,10) d,and the length of hospital stay was 11(9,13) d,which was shorter than the control group[10(7,11) days,12(10.5,13.5) d],the difference between groups was statistically significant (P <0.05).The disappearance rate of cough,phlegm,throat discomfort,xerostomia and other symptoms in the experimental group was better than that in the control group.No severe cases or death occurred in the two groups,and no treatment-related adverse events were observed.[Conclusion] In the treatment of Omicron virus strain infected COVID-19,XFBD can relieve the symptoms,shorten the time of viral nucleic acid negative conversion safely.
Key words:  COVID-19  Omicron strain  traditional Chinese medicine  Xuanfei Baidu Granule  clinical evaluation
关注公众号二维码